Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases. (15th November 2016)

• Record Type: Journal Article
• Authors: Semb, A.G.; Ikdahl, E.; Hisdal, J.; Olsen, I.C.; Rollefstad, S.
• Is Part Of: International journal of cardiology. Volume 223(2016)
• Page Start: 331
• Page End: 336
• Publication Date: 2016-11-15
• Subjects: Risk factor -- Cardiovascular disease -- Prevention -- Inflammatory joint disease; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.08.129
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Objectives: Cardiovascular disease (CVD) risk calculators developed for the general population have been shown to inaccurately predict CVD events in patients with inflammatory joint disease (IJD). European guidelines for CVD prevention recognize the presence of carotid plaques (CP) as a very high CVD risk factor, equivalent of coronary artery disease. Patients with IJD have a high prevalence of CP. We evaluated if CP resulted in reclassification of patients with IJD into a more appropriate CVD risk class and recommended lipid lowering treatment. Methods: CVD risk evaluation was performed in patients with IJD using SCORE and ACC/AHA risk calculators to predict CVD events. Results: Of the 335 IJD patients evaluated (including rheumatoid arthritis n = 201, ankylosing spondylitis n = 85 and psoriatic arthritis n = 49), 183 and 159 IJD patients had a calculated CVD risk by SCORE and ACC/AHA < 5%, indicating no need of lipid lowering treatment (LLT). However, of patients with low to moderate risk calculated by SCORE and ACC/AHA, 67 (36.6%) and 48 (30.2%) had CP and should according to guidelines receive intensive LLT. For patients with high risk, in the LLT considered group, 54.9% and 58.1% were reclassified to correct treatment when adding information on the presence of CP. Our results reveal a considerable reclassification into correct CVD risk category when adding CP in female patients. Conclusion: The high frequency of asymptomatic atherosclerosis in patients with IJD has a notable impact on CVD risk stratification. Identification of CP will reclassify patients into recommended CVD preventive treatment group, which may be clinically important.